The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa

Annals of Pharmacotherapy

Volumn 43, Issue 7-8, 2009, Pages 1203-1210

  Song, Xue ^a   Long, Stacey R ^a   Marder, William D ^a   Sullivan, Sean D ^b   Kallich, Joel ^c  

^a THOMSON REUTERS   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c AMGEN INC   (United States)

Author keywords

Claims data; Comparative study; Cost analysis; Erythropoiesis stimulating agents

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; COMORBIDITY; DATABASES, FACTUAL; DRUG COSTS; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 67651113989     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L590     Document Type: Article

References (14)

1. Fortner B, Tauer K, Zhu L, Ma L, Schwartzberg L. The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: a national survey. Commun Oncol 2004;1:1-7.
2. Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy- induced anemia. Clin Ther 2003;25:2781-2796 (Pubitemid 37510589)
3. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004;9:451-458 (Pubitemid 39014556)
4. Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health System Pharm 2005;62:54-62. (Pubitemid 40394635)
5. Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μ g every 2 weeks). Oncologist 2005;10:642-650
6. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every 2-week darbepoetin-alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-2297 (Pubitemid 46630659)
7. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707.
8. Hoffman JM, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures-2006. Am J Health Syst Pharm 2006;63:123-138
9. Chen ER, Peake C, Buscaino E, et al. Hematologic outcomes and erythropoiesis- stimulating therapy costs in epoetin alfa (EPO)- and darbepoetin alfa (darbepoetin alfaRB)-treated cancer patients: results of the Dosing and Outcomes Study of Erythropoeisis-Stimulating Therapies (D.O.S.E.) Registry (abstract). Blood 2006;109:p953a.
10. Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 2006;9:1623-1631 (Pubitemid 44449217)
11. Berger A, Edelsberg J, Kallich J, Oster G. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia. Clin Ther 2008;30:206-218 (Pubitemid 351836066)
12. Aranesp prescribing information. In: Physician's desk reference. 60th ed. Montvale, NJ: Medical Economics Data, 2006:576-580
13. Procrit prescribing information. In: Physician's desk reference. 60th ed. Montvale, NJ: Medical Economics Data, 2006:2374-2382
14. Agency for Healthcare Research and Quality. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. http://effectivehealthcare.ahrq.gov/reports/topic.cfm? topic=2&sid=33&rType=3 (accessed 2009 Mar 30).